Exciting News from Collegium Pharmaceutical: Real-World Data on Jornay PM at NAPNAP 2025
In a recent press release, Collegium Pharmaceutical, Inc., a leading specialty pharmaceutical company, shared some intriguing news. The company announced that it will showcase two poster presentations at the National Association of Pediatric Nurse Practitioners (NAPNAP) 46th National Conference on Pediatric Health Care, taking place in Chicago, IL, from March 10-13, 2025.
Jornay PM: A Differentiated Neuropsychiatry Product
The presentations will focus on real-world data from Collegium’s neuropsychiatry product, Jornay PM (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD). Jornay PM is designed to offer a few unique advantages over other ADHD medications. It utilizes Collegium’s OROS-AD Technology, which is a controlled-release technology that provides a consistent, steady-state plasma concentration of methylphenidate over an extended 8-hour dosing period.
Benefits of Jornay PM
The steady-release formulation of Jornay PM aims to minimize the need for frequent dosing, which can be a significant inconvenience for patients and caregivers. Additionally, this technology may help reduce the risk of peak-dose side effects, such as appetite loss, insomnia, and irritability, that are commonly associated with immediate-release methylphenidate.
Impact on Individuals with ADHD
For individuals with ADHD, the convenience and potential side effect reduction offered by Jornay PM could lead to improved medication adherence and better overall symptom management. This is a crucial aspect, as research suggests that only about 20-30% of children with ADHD receive appropriate treatment, and even among those who do, only about half adhere to their medication regimen as prescribed.
Global Implications
The potential benefits of Jornay PM extend beyond individual patients. Improved medication adherence and symptom management can lead to better educational, social, and professional outcomes for individuals with ADHD. Furthermore, better management of ADHD symptoms can lead to reduced healthcare costs, as untreated ADHD can result in increased healthcare utilization and higher societal costs.
A Closer Look at the NAPNAP Conference
The National Association of Pediatric Nurse Practitioners (NAPNAP) 46th National Conference on Pediatric Health Care is an annual event that brings together pediatric nurse practitioners, researchers, and industry professionals to discuss the latest advances and trends in pediatric health care. This year’s conference, held in Chicago, IL, from March 10-13, 2025, is expected to attract over 2,500 attendees and feature numerous educational sessions, poster presentations, and networking opportunities.
Conclusion
The announcement of Collegium Pharmaceutical’s two poster presentations on Jornay PM at the NAPNAP 46th National Conference on Pediatric Health Care marks an exciting development for individuals with ADHD and the healthcare community as a whole. The potential benefits of Jornay PM, including improved medication adherence and reduced side effects, could lead to better outcomes for patients and significant cost savings for society. Stay tuned for more updates on this intriguing topic as the conference unfolds.
- Collegium Pharmaceutical to present real-world data on Jornay PM at NAPNAP 2025
- Jornay PM is a neuropsychiatry product for the treatment of ADHD
- Utilizes OROS-AD Technology for consistent, steady-state plasma concentration
- May minimize inconvenience and reduce side effects compared to immediate-release methylphenidate
- Potential for improved medication adherence and better symptom management
- Cost savings for society through reduced healthcare utilization
- NAPNAP 46th National Conference on Pediatric Health Care attracts over 2,500 attendees
